| Critical Outcome Technologies Inc |
|
Our business is disease specific drug discovery, optimization and pre-clinical development using a specially developed series of computer models. Our approach allows us to discover potential new drug candidate therapies faster, cheaper and more efficiently than our competitors who still largely rely on traditional wet lab iterative methods and thus accelerate the timeline and reduce the cost to develop new drugs. Our focus is on the discovery and pre-clinical development of small molecules for the treatment of serious diseases for which current therapy is either lacking or ineffective. We currently have five targeted libraries of small molecules (small cell lung cancer, adult onset acute myelogenous leukemia, colorectal cancer, human immunodeficiency virus (HIV), and multiple sclerosis) under active development. The future of drug discovery is here.
contact: Mr. Michael Barr, Director of Marketing & Business Development 519.858.5157 |
